<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850160</url>
  </required_header>
  <id_info>
    <org_study_id>005-12 HTA</org_study_id>
    <nct_id>NCT01850160</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension</brief_title>
  <official_title>Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farma de Colombia SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Farma de Colombia SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is aimed to assess the efficacy and safety of a fixed-dose combination therapy
      with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone alone for treatment of
      adult patients with diagnosis of arterial hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In spite of the existence of a great variety of treatments with drugs effective against
      arterial hypertension, the percentages of arterial hypertension control with monotherapy
      remain quite low reason why the fixed-dose combinations of drugs have been one of the most
      interesting research topics in order to achieve an appropriate control of arterial
      hypertension.

      The possibility of achieving better coverage and Blood Pressure control through a drug
      combination has leaded, on a scientific base of the efficacy of an Angiotensin Receptor
      Blockers II plus diuretic combination, to the development of a great number of combinations
      with different Angiotensin II Receptor Blockers plus hydrochlorothiazide. Yet it is
      noteworthy that despite the increasing evidence showing additional benefits in Blood pressure
      control and reduction of cardiovascular outcomes with chlorthalidone over
      hydrochlorothiazide, there is neither a great number of combinations nor studies with
      Angiotensin II Receptor Blockers plus chlorthalidone whereby the conduction of a trial
      assessing the efficacy and safety of Valsartan plus chlorthalidone in hypertensive patients
      is proposed plus the benefits of combination therapy that include, among others, the greater
      efficacy with lower doses of each individual component as well as reduction in occurrence of
      adverse events directly related with lower drug doses.With this treatment schedule it is
      expected to obtain higher control of blood pressure values and greater percentage of
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Efficacy of the fixed-dose combination treatment with Valsartan plus Chlorthalidone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy and safety of a fixed-dose combination treatment of Valsartan plus Chlorthalidone Vs Valsartan or Chlorthalidone alone in the treatment of patients with arterial hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Systolic and Diastolic Blood pressure values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the changes in Systolic and Diastolic Blood Pressure from baseline up to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Systolic blood pressure values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the changes of systolic blood pressure from baseline up to week 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Diastolic blood pressure values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the changes of diastolic blood pressure from baseline up to week 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of diastolic blood pressure in arterial blood pressure median values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the changes in diastolic blood pressure in Arterial Blood Pressure Media from baseline up to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of systolic blood pressure values in arterial blood pressure median values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the change in systolic blood pressure in Arterial Blood Pressure Median from baseline up to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient that achieving blood pressure values lower than 140/90 (systolic/diastolic) at week 6 and 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the percentage of patients achieving blood pressure values lower than 140/90 (systolic/diastolic) at weeks 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients that achieving systolic blood pressure values lower than 140 at week 6 and 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the percentage of patients achieving systolic blood pressure lower than 140 at weeks 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients that achieving diastolic blood pressure values lower than 90 at week 6 and 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the percentage of patients achieving diastolic blood pressure lower than 90 at week 6 and 12</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolic changes secondary to the treatment with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Identify if there are significant differences regarding metabolic changes secondary to the treatment with Valsartan and Chlorthalidone Vs Valsartan or Chlorthalidone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events in each intervention group</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the percentage of incidence of adverse events in each intervention group.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>GROUP A: Valsartan plus Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP B: Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP C: Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP A: Valsartan plus Chlorthalidone</intervention_name>
    <description>Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.</description>
    <arm_group_label>GROUP A: Valsartan plus Chlorthalidone</arm_group_label>
    <other_name>Chlorthalidone Drug Combination</other_name>
    <other_name>Valsartan Drug Combination</other_name>
    <other_name>Antihypertensive Agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP B: Valsartan</intervention_name>
    <description>GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.</description>
    <arm_group_label>GROUP B: Valsartan</arm_group_label>
    <other_name>Angiotensin II Receptor Antagonist</other_name>
    <other_name>Antihypertensive Agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP C: Chlorthalidone</intervention_name>
    <description>GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.</description>
    <arm_group_label>GROUP C: Chlorthalidone</arm_group_label>
    <other_name>Sodium Chloride Symporter Inhibitors</other_name>
    <other_name>Antihypertensive Agents</other_name>
    <other_name>Diuretics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with diagnosis of arterial hypertension defined as:

          -  Systolic blood pressure greater or equal to 140 and lower than 180 mmHg

          -  Diastolic blood pressure greater or equal to 90 and lower than 110 mmHg

          -  Non controlled patients with antihypertensive treatment (blood pressure values:
             Systolic blood pressure &gt; 140 mmHg and/or Diastolic blood pressure &gt; 90 mmHg) or
             patients antihypertensive treatment-naïve.

          -  Likelihood of attending consultations according to the trial chronogram.

          -  Informed Consent Signature.

        Exclusion Criteria:

          -  Diagnosis of severe or malignant arterial hypertension defined as:

          -  Systolic blood pressure greater or equal to 180 mmHg

          -  Diastolic blood pressure greater or equal to 110 mmHg

          -  Patients with secondary arterial hypertension of any etiology.

          -  Pregnant women or women with childbearing potential who are not using appropriate
             contraception methods; women planning to become pregnant during the trial.

          -  Patients with history of Acute Myocardial Infarction o Angina Pectoris within the 6
             months prior to the trial initiation.

          -  Diagnosis of Cerebrovascular Disease (CVD) o Transient Ischemic Attack (TIA) within
             the 6 previous months.

          -  Patients with Severe Renal Disease defined by serum Creatinine levels higher than 1.5
             mg/dl.

          -  Diagnosed or suspected unilateral or bilateral renal artery stenosis.

          -  History of non remitting cancer within the 5 years prior to the trial initiation.

          -  Patients with Hypokalemia or Hyperkalemia.

          -  Patients receiving Valsartan or Chlortalidone during the 14 previous days.

          -  Patients with known hypersensitivity to Valsartan or Chlorthalidone.

          -  Unstable patients with antecedent of hospitalization within the 4 days prior to their
             enrollment in the trial.

          -  Patients with history of drugs and alcohol abuse within the last year.

          -  Patients who have taken part in other clinical trial within the 4 weeks prior to the
             initiation of this research.

          -  Patients with any other clinical condition that the investigator deems may affect the
             patient follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan D Romero, MD</last_name>
    <role>Study Director</role>
    <affiliation>Farma de Colombia SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Diagnostico Cardiologico</name>
      <address>
        <city>Cartagena</city>
        <state>Bolivar</state>
        <zip>130001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardiomet Cequin</name>
      <address>
        <city>Armenia</city>
        <state>Quindio</state>
        <zip>630001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPlus</name>
      <address>
        <city>Bogota DC</city>
        <zip>11001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro AMCOR</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico quirurgico</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro médico de hipertensión arterial</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica DAME</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Edificio Novoa</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Ecuador</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>High blood pressure</keyword>
  <keyword>Drug therapy combination</keyword>
  <keyword>Valsartan</keyword>
  <keyword>Chlorthalidone</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

